gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NYSE · MRKHealthcarePharmaceuticals

Merck & Co., Inc. (MRK)

$150.36+3.93%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$148.97▲ 80.59% in range
Nov 3, 2025Low $82.49 · High $156.45Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Merck & Co. closed at $150.36 on Nov 4, up 3.93%, 3.9% below its 52-week closing high. Volume of 10.7M shares was 1.04× its 20-day average (close to normal).

Split-adjusted performance: +5.9% over one month, +32.4% over six months, +82.3% over one year.

In the quarter ended Jun 30, 2026, revenue was $16.61B, up 5.1% from a year earlier, with a net margin of -8.0%.

Short interest was 26.8M shares at the Oct 15 settlement, down 5.1% from the prior report (1.1% of float, 3.0 days to cover).

Market cap$370.96B2.47B shares
Revenue · quarter$16.61B+5.1% YoY
Diluted EPS$-0.54−130.7% YoY
P/E · TTM116.9×P/S 5.6×
Net margin-8.0%Gross 73.5%
Dividend yield2.26%$0.85 last paid
52-week range82.49 – 156.45−3.9% from high
Volume10.7M1.04× 20-day avg
Volatility · 60d37.1%Annualised
Short % of float1.1%3.0 days to cover
Net cash-$46.77BCash $7.14B
Next earnings—Not scheduled
Split-adjusted performance
1W +6.7%1M +5.9%3M +17.1%6M +32.4%YTD +42.8%1Y +82.3%3Y +46.4%5Y +84.4%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum87
Revenue growth47
Net margin64
Value (low P/E)7
Size99

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short26.8M−5.1% vs prior
Days to cover3.0Settled Oct 15
% of float1.1%
Short vol. 10d34.1%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
MRKMerck & Co.$150.36+3.93%+32.4%+5.1%−8.0%116.9$370.96B
ABBVABBVIE$294.83+3.09%+43.8%+10.3%24.2%50.4$521.00BCompare
JNJJohnson & Johnson$276.32+3.81%+23.0%+5.9%0.8%41.3$665.19BCompare
ABTAbbott Laboratories$115.51+5.58%+33.8%+13.0%7.4%36.8$199.88BCompare
PFEPfizer$30.79+2.63%+16.1%+2.6%−1.6%40.5$175.49BCompare
VRTXVertex Pharmaceuticals$549.04+3.44%+28.4%+11.8%19.0%35.0$139.16BCompare
BMYBristol-Myers Squibb$64.19+4.02%+13.4%+5.7%25.6%14.1$131.21BCompare
LLYEli Lilly &$1,417.99+0.61%+43.7%+38.6%26.4%45.8$1.26TCompare
REGNRegeneron Pharmaceuticals$930.67−4.39%+29.1%+36.3%38.1%20.0$96.28BCompare

News about Merck & Co.

All news →
Medicenna Completes Phase 1/2 ABILITY-1 Enrollment and Announces Webinar to Discuss Updated MDNA11 Results with Key Opinion LeadersGlobeNewswire Inc. · 18h agoNeutralMerck to Divest CDMO Business to LonzaGlobeNewswire Inc. · 2d ago▲ PositiveWhy Merck Stock Flew Higher on FridayThe Motley Fool · 5d ago▲ PositiveMerck Q3 Earnings Call Highlights Pipeline Progress and Raised OutlookZacks Investment Research · 5d ago▲ PositiveMRK Q3 Earnings & Sales Beat Estimates, '26 EPS View Raised, Stock UpZacks Investment Research · 6d ago▲ Positive

Quick answers

What does Merck & Co. do?
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. In cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales.
What is MRK's market cap?
$370.96B, based on the Nov 4 close of $150.36.
What is MRK's P/E ratio?
116.9× trailing-twelve-month earnings of $3.17B.
Does Merck & Co. pay a dividend?
Yes. The latest regular dividend was $0.85 per share (ex-date Sep 15), an annualised yield of 2.26%.
How much of MRK is sold short?
26.8M shares, 1.1% of float, as of Oct 15, 2026.
What sector is MRK in?
Healthcare, in the Pharmaceuticals industry.

About Merck & Co.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. In cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 53% of the company's 2025 sales were generated from US human health (pharmaceuticals and vaccines).

HQ: Rahway, NJ75,000 employeesListed Apr 20, 1949merck.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology